Home

prova corrompere cubo gabriella farina fatebenefratelli bobina Temporale Costruire

Adjuvant chemotherapy in gastric cancer: 5-year results of a randomised  study by the Italian Trials in Medical Oncology (ITMO) Group - Annals of  Oncology
Adjuvant chemotherapy in gastric cancer: 5-year results of a randomised study by the Italian Trials in Medical Oncology (ITMO) Group - Annals of Oncology

Awareness and consideration of malnutrition among oncologists: Insights  from an exploratory survey
Awareness and consideration of malnutrition among oncologists: Insights from an exploratory survey

Gabriella Farina | Medici | ASST FBF SACCO
Gabriella Farina | Medici | ASST FBF SACCO

Italian Nivolumab Expanded Access Program in Nonsquamous Non–Small Cell  Lung Cancer Patients: Results in Never-Smokers and EGFR-Mutant Patients -  Journal of Thoracic Oncology
Italian Nivolumab Expanded Access Program in Nonsquamous Non–Small Cell Lung Cancer Patients: Results in Never-Smokers and EGFR-Mutant Patients - Journal of Thoracic Oncology

Scanned Document
Scanned Document

20+ "Gabriella Farina" profiles | LinkedIn
20+ "Gabriella Farina" profiles | LinkedIn

Guidelines Adaptation to the COVID-19 Outbreak for the Management of  Hepatocellular Carcinoma | Journal of Laparoendoscopic & Advanced Surgical  Techniques
Guidelines Adaptation to the COVID-19 Outbreak for the Management of Hepatocellular Carcinoma | Journal of Laparoendoscopic & Advanced Surgical Techniques

ASST Fatebenefratelli & SACCO | ESMO
ASST Fatebenefratelli & SACCO | ESMO

Gabriella Farina's research works | Azienda Ospedaliera Fatebenefratelli e  Oftalmico Milano (Fatebenefratelli) and other places
Gabriella Farina's research works | Azienda Ospedaliera Fatebenefratelli e Oftalmico Milano (Fatebenefratelli) and other places

A randomized, phase 2 study of cetuximab plus cisplatin with or without  paclitaxel for the first-line treatment of patients with recurrent and/or  metastatic squamous cell carcinoma of the head and neck -
A randomized, phase 2 study of cetuximab plus cisplatin with or without paclitaxel for the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck -

Nutritional Support in Cancer patients: update of the Italian Intersociety  Working Group practical recommendations
Nutritional Support in Cancer patients: update of the Italian Intersociety Working Group practical recommendations

Il caregiver in oncologia: una guida per sostenere il malato | Fondazione  Aiom
Il caregiver in oncologia: una guida per sostenere il malato | Fondazione Aiom

Italian Cohort of the Nivolumab EAP in Squamous NSCLC: Efficacy and Safety  in Patients With CNS Metastases | Anticancer Research
Italian Cohort of the Nivolumab EAP in Squamous NSCLC: Efficacy and Safety in Patients With CNS Metastases | Anticancer Research

Nutrients | Free Full-Text | The Clinical Value of Nutritional Care before  and during Active Cancer Treatment | HTML
Nutrients | Free Full-Text | The Clinical Value of Nutritional Care before and during Active Cancer Treatment | HTML

Sabato 7 Aprile corso Unitalsi: "la fine della vita" - CiaoComo
Sabato 7 Aprile corso Unitalsi: "la fine della vita" - CiaoComo

Palliative Sedation in Terminal Cancer Patients Admitted to Hospice or Home  Care Programs: Does the Setting Matter? Results From a National Multicenter  Observational Study - Journal of Pain and Symptom Management
Palliative Sedation in Terminal Cancer Patients Admitted to Hospice or Home Care Programs: Does the Setting Matter? Results From a National Multicenter Observational Study - Journal of Pain and Symptom Management

Randomised Phase II Trial (NCT00637975) Evaluating Activity and Toxicity of  Two Different Escalating Strategies for Pregabalin and Oxycodone  Combination Therapy for Neuropathic Pain in Cancer Patients | PLOS ONE
Randomised Phase II Trial (NCT00637975) Evaluating Activity and Toxicity of Two Different Escalating Strategies for Pregabalin and Oxycodone Combination Therapy for Neuropathic Pain in Cancer Patients | PLOS ONE

Gabriella Farina's research works | Azienda Ospedaliera Fatebenefratelli e  Oftalmico Milano (Fatebenefratelli) and other places
Gabriella Farina's research works | Azienda Ospedaliera Fatebenefratelli e Oftalmico Milano (Fatebenefratelli) and other places

Consiglio di Amministrazione </br> 2016-2019 | Fondazione Aiom
Consiglio di Amministrazione </br> 2016-2019 | Fondazione Aiom

Gabriella Farina's research works | Azienda Ospedaliera Fatebenefratelli e  Oftalmico Milano (Fatebenefratelli) and other places
Gabriella Farina's research works | Azienda Ospedaliera Fatebenefratelli e Oftalmico Milano (Fatebenefratelli) and other places

Multicenter, randomised, open-label, non-comparative phase 2 trial on the  efficacy and safety of the combination of bevacizumab and trabectedin with  or without carboplatin in women with partially platinum-sensitive recurrent  ovarian cancer
Multicenter, randomised, open-label, non-comparative phase 2 trial on the efficacy and safety of the combination of bevacizumab and trabectedin with or without carboplatin in women with partially platinum-sensitive recurrent ovarian cancer

Nutrients | Free Full-Text | The Role of Nutritional Support for Cancer  Patients in Palliative Care | HTML
Nutrients | Free Full-Text | The Role of Nutritional Support for Cancer Patients in Palliative Care | HTML

Overall Survival in Metastatic Breast Cancer Patients in the Third  Millennium: Results of the COSMO Study∗ - Clinical Breast Cancer
Overall Survival in Metastatic Breast Cancer Patients in the Third Millennium: Results of the COSMO Study∗ - Clinical Breast Cancer

The prognostic role of tumor size in early breast cancer in the era of  molecular biology | PLOS ONE
The prognostic role of tumor size in early breast cancer in the era of molecular biology | PLOS ONE

Rationale for Treatment and Study Design of TAILOR: A Randomized Phase III  Trial of Second-line Erlotinib Versus Docetaxel in the Treatment of  Patients Affected by Advanced Non–Small-Cell Lung Cancer With the Absence
Rationale for Treatment and Study Design of TAILOR: A Randomized Phase III Trial of Second-line Erlotinib Versus Docetaxel in the Treatment of Patients Affected by Advanced Non–Small-Cell Lung Cancer With the Absence

Presentazione standard di PowerPoint
Presentazione standard di PowerPoint